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Background/aim: Despite the fact that the COVID-19 pandemic has been going on for over 5 months, there is yet to be a standard
management policy for all patients including those with mild-to-moderate cases. We evaluated the role of early hospitalization in
combination with early antiviral therapy with COVID-19 patients in a tertiary care university hospital.
Materials and methods: This was a prospective, observational, single-center study on probable/confirmed COVID-19 patients
hospitalized in a tertiary care hospital on COVID-19 wards between March 20 and April 30, 2020. The demographic, laboratory, and
clinical data were collected.
Results: We included 174 consecutive probable/confirmed COVID-19 adult patients hospitalized in the Internal Medicine wards of the
University Adult Hospital between March 20 and April 30, 2020. The median age was 45.5 (19–92) years and 91 patients (52.3%) were
male. One hundred and twenty (69%) were confirmed microbiologically, 41 (23.5%) were radiologically diagnosed, and 13 (7.5%) were
clinically suspected (negative microbiological and radiological findings compatible with COVID-19); 35 (20.1%) had mild, 107 (61.5%)
moderate disease, and 32 (18.4%) had severe pneumonia. Out of 171 cases, 130 (74.3%) showed pneumonia; 80 were typical, and 50
showed indeterminate infiltration for COVID-19. Patients were admitted within a median of 3 days (0-14 days) after symptoms appear.
The median duration of hospitalization was 4 days (0-28 days). In this case series, 13.2% patients were treated with hydroxychloroquine
alone, 64.9% with hydroxychloroquine plus azithromycin, and 18.4% with regimens including favipiravir. A total of 15 patients (8.5%)
were transferred to the ICU. Four patients died (2.2%).
Conclusion: In our series, 174 patients were admitted to the hospital wards for COVID-19, 69% were confirmed with PCR and/or antibody
test. At the time of admission, nearly one fifth of the patients had severe diseases. Of the patients, 95.4% received hydroxychloroquine
alone or in combination. The overall case fatality rate was 2.2%.
Key words: COVID-19, noncritical illness, hydroxychloroquine, favipiravir

1. Introduction
As of mid-June, 2020 the number of COVID-19 cases
exceeded seven and a half million and more than 425
thousand deaths were reported worldwide 1. Currently,

Turkey ranks at 12 in the list of countries with the highest
number of cases, with a total number of infected patients
reaching 170,000, with more than 4000 deaths in the
3 months after the first COVID-19 case was reported

1
World Health Organization (2020). Coronavirus Disease (COVID-19) Situation Report [online]. Website: https://www.who.int/docs/default-source/
coronaviruse/situation-reports/20200513-covid-19-sitrep-114.pdf?sfvrsn=17ebbbe_4 [accessed 06 06 2020].
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on March 11, 20202. Despite an initial decline of new
emerging cases, the pandemic is far from ceasing and
new wave(s) of emerging cases are expected in the wake
of removing strict lockdown measures. Since no highly
effective antivirals and vaccines are available so far, the
management strategies of patients to reduce morbidity
and mortality are of utmost importance.
In this report, we present the first cohort of COVID-19
cases in a Turkish university hospital in Ankara where
early admission to the hospital and a variety of antiviral
drugs are provided. To the best of our knowledge, this is
the largest and most detailed report about demographics,
clinical, and laboratory characteristics and outcomes of
patients diagnosed with probable/confirmed COVID-19
admitted to the intensive care unit (ICU) wards in a
Turkish university hospital.
2. Materials and methods
This was a prospective, observational, single-center
study on probable and confirmed COVID-19 patients
hospitalized in a university hospital for adults. Local
ethics committee approval was obtained (GO 20/354).
We included adult patients (≥18 years old) hospitalized
in COVID-19 wards between March 20 and April 30,
2020. Critically ill patients with sepsis and/or acute
respiratory distress syndrome requiring ICU care at the
time of admission were excluded. Treatment and discharge
decision were made by attending physicians according to
the current national guidelines prepared by the Scientific
Advisory Committee of the Turkish Ministry of Health3 .
The patients were classified into confirmed and
probable cases. The ‘confirmed case’ was a patient with
positive SARS-CoV-2 RT-PCR from nasopharyngeal swab
or a positive SARS-CoV-2 antibody test. The ‘probable
case’ was further divided into ‘clinically suspected’ and
‘radiologically diagnosed’ categories. A ‘clinically suspected
case’ was defined as a patient with sudden onset of fever,
cough, or dyspnea, who had acute respiratory symptoms
that could not be explained with any other cause, and who
tested negative for SARS-CoV-2 RT-PCR plus a negative
pulmonary imaging test3. The ‘radiologically diagnosed’
patient was a clinically suspected case who also had chest
imaging findings compatible with COVID-19.
Microbiological confirmation was performed using
nasopharyngeal sampling [3]. Viral nucleic acid isolation

from the samples was achieved by using Bio-Speedy vNAT
viral nucleic acid buffer (Bioeksen R&D Technologies Ltd,
Turkey). The COVID-19 real-time (RT) PCR kit (Bioeksen
R&D Technologies Ltd, Turkey) used in this study was
designed to detect SARS-CoV-2 causing COVID-19. The
kit is applied to nucleic acid isolates from nasopharyngeal
swab, oropharyngeal swab, nasopharyngeal aspirate,
nasopharyngeal aspirate lavage, bronchoalveolar lavage,
and sputum samples. The detection is achieved via onestep reverse transcription and RT-PCR targeting SARSCoV-2-specific RdRp (RNA-dependent RNA polymerase)
gene fragment. The analytical sensitivity and accuracy
of the kit are given by the company as 99.4% and 99.0%
respectively. If the first RT-PCR test was negative, a
second PCR was ordered after 24 to 48 h. If the second
PCR test was negative, SARS-CoV-2 total antibody test
[COVID-19 IgM/IgG Ab Test Cassette (Colloidal Gold)
(Hotgen, P.R.China)] was performed following the
directions of the supplier3. Once the patient was admitted,
chest imaging was performed by X-ray and/or low-dose
computerized tomography (CT) of the chest at a radiology
unit allocated for COVID-19 suspected cases. CT scans
were evaluated and reported by a radiologist as a routine
practice; the findings were classified as negative, typical, or
indeterminate for COVID-19 according to the American
College of Radiology definitions [1].
We further classified patients into three categories
based on the severity of the clinical presentation according
to World Health Organization (WHO) classification4: Mild
disease was defined as uncomplicated upper respiratory
tract viral infection with no documented pneumonia
and accompanied by nonspecific symptoms such as fever,
fatigue, cough (with or without sputum production),
anorexia, malaise, muscle pain, sore throat, dyspnea, nasal
congestion, or headache. Patients with pneumonia with no
signs of severe pneumonia and no need for supplemental
oxygen were classified as “moderate disease”. Severe
pneumonia was defined as fever or suspected respiratory
infection, plus one of the following: respiratory rate >30
breaths/min; severe respiratory distress; or O2 saturation
through pulse oximetry (SpO2) ≤ 93% on room air5.
The demographics (age, sex, contact history with
COVID-19, travel history), medical information
(concurrent medical illnesses, medications), symptoms
(fever, cough, sore throat, dyspnea, myalgia, nasal

2
Republic of Turkey Ministry of Health (2020). Novel coronavirus actual state, 06 June 2020 [online]. Website: https://covid19.saglik.gov.tr/ [accessed
06 June 2020].
3
Republic of Turkey Ministry of Health Directorate General of Public Health (2020). COVID-19 (SARS-CoV-2 Infection) guide (in Turkish) [online].
Website: https://covid19bilgi.saglik.gov.tr/depo/rehberler/COVID-19_Rehberi.pdf [accessed 14 April 2020].
4
Republic of Turkey Ministry of Health Directorate General of Public Health (2020). COVID-19 (SARS-CoV-2 Infection) guide (in Turkish) [online].
Website: https://covid19bilgi.saglik.gov.tr/depo/rehberler/COVID-19_Rehberi.pdf [accessed 14 April 2020].
5
World Health Organization (2020). Clinical Management of Severe Acute Respiratory Infection (SARI) When COVID-19 Diseases is Suspected.
Interim Guidance, 13 March 2020 [Online]. Website: https://apps.who.int/iris/handle/10665/331446 [accessed 14 April 2020].
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discharge, sputum, fatigue, smell or taste loss, diarrhea),
and the date the symptoms started were recorded according
to the patients’ declaration. Vital signs (temperature,
pulse, respiration rate, pulse oxygen saturation, and
blood pressure) were recorded daily. Laboratory tests for
complete blood count, alanine aminotransferase (ALT),
aspartate aminotransferase (AST), lactate dehydrogenase
(LDH), blood urea nitrogen (BUN), creatinine, C-reactive
protein (CRP), procalcitonin, D-dimer, ferritin,
fibrinogen, troponin I, creatine kinase (CK), creatine
kinase myocardial band (CK-MB), and triglyceride levels
were recorded. The need for oxygen support (oxygen via
nasal cannula or mask) was noted. The Modified Early
Warning Score (MEWS) of the patients was recorded on
the admission date [2,3]. The patients were followed until
discharge, transfer to the ICU or death in the wards. The
patients not discharged or deceased on April 30 were
followed up until May 10, 2020.
The treatment regimen for each patient was decided
upon by the primary physician and the consulting team
from the Department of Infectious Diseases. We divided
treatment regimens into three groups: hydroxychloroquine
(HQ)-only, HQ plus azithromycin (AZ), and favipiravir
(FAV)-containing regimens. FAV was used in combination
with, or as a sequential therapy to the first line treatment
regimens (HQ ± AZ) in cases with noncritical illness,
but extensive bilateral pneumonia. Twelve-derivation
electrocardiogram was obtained initially from all
hospitalized patients, and ECG monitoring was performed
every other day for patients receiving HQ and/or AZ.
Adverse reactions under treatments were defined
as nausea/vomiting requiring antiemetic medication,
QT prolongation of >500 ms, arrhythmia, elevation of
transaminases >100 U/L, and stopping of antiviral therapy
due to any adverse effects during follow-up in the wards.
We compared treatment regimens in terms of the
time to defervescence (the return of body temperature
to normal (<38.0 °C) during the hospital stay) and
time to clinical improvement on therapy. The clinical
improvement was defined when any of the following
was observed: resolution of fever, dyspnea, oxygen need,
respiratory failure, or discharge.
2. Statistical analysis
Continuous variables were given as mean ± standard
deviation if normally distributed, and median (minimum–
maximum) for nonnormally distributed variables.
Categorical variables were summarized as counts and
percentages. The treatment groups were compared with
the Kruskal–Wallis test and pairwise comparisons.
The Dunn test was applied for pairwise comparisons.
The relationships between categorical variables were

determined using the chi square test. P-value <0.05 was
accepted as statistical significance.
3. Results
A total of 174 consecutive patients with probable/confirmed
COVID-19 hospitalized in the Internal Medicine wards of
the Hacettepe University Adult Hospital between March
20 and April 30, 2020 were included. The median age was
45.5 years (19–92 years) with a preponderance of males (91
patients, 52.3%). Overall, 120 (69%) cases were confirmed
microbiologically, 41 (23.5%) were radiologically
diagnosed, and 13 (7.5%) were clinically suspected.
The most frequent symptoms were fatigue (n: 127,
72.9%), cough (n: 125, 71.8%), and fever (n: 104, 60%)
(Table 1). Less than half of the cases (n: 82, 47.1%) had
contact history with a COVID-19 patient. Only one had
a history of international travel. According to WHO
definitions, 35 (20.1%) had mild disease, 107 (61.5%) had
moderate, and 32 (18.4%) had severe disease (Table 1).
Median time from the first appearance of symptoms to the
first hospital admission was 3 (0–14) days.
The vital signs and MEWS score of probable/confirmed
COVID-19 patients at the time of admission and during
hospitalization period are given in Table 2.
All patients underwent RT-PCR testing for COVID-19
and 25 had antibody testing done 3–5 days after the second
negative RT-PCR test results. A hundred and thirteen
(64.6%) were RT-PCR–positive (109 in the first, an
additional four in the second RT-PCR testing) and seven
tested positive for IgM/IgG total antibodies. CT scans
of the chest were performed in all cases except for three
patients. Three-quarters of them (n: 130, 74.3%) revealed
pneumonia; 80 were typical of, and 50 indeterminate for
COVID-19 infiltration (Table 3).
Three-thirds of the patients (n: 116, 66.7%) had
lymphopenia (<1500 / mm3) , and 39 (22.4%) had severe
lymphopenia (<800 / mm3) at the time of admission (Table
4). C-reactive protein was >4 mg/dL in 40 (22.9%), and
D-dimer was >1.0 mg/L in 36 (20.6%) of the cases at the
beginning of hospitalization. In 19 (10.9%) cases serum
ferritin level was >500 µg/L. Significant differences were
observed among the three categories of disease (mild,
moderate and severe) in regards to white blood cell,
lymphocyte, neutrophil count, NLR, serum LDH, BUN,
CRP, procalcitonin, ferritin, D-dimer, and troponin I
levels (Table 4).
Multiplex RT-PCR tests for viral (n = 148) and bacterial
respiratory pathogens (n = 147) were performed from
nasopharyngeal swab samples using Allplex Respiratory
Panel (Seegene, South Korea). Only 5 samples (3.4%)
were positive for another viral pathogen, and 19 samples
(12.9%) were positive for at least one bacterial pathogen,
in 23 COVID-19 patients (Table 5). Only in one clinically
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Table 1. Demographic characteristics of probable/confirmed COVID-19 patients.
Characteristics

Total

Mild disease

Moderate disease

Severe disease

Number of cases, %

174 (100)

35 (20.1)

107 (61.5)

32 (18.4)

Age, years, median range
≥65 years, n (%)

45.5
19–92
24 (13.8)

44
(24–82)
6

42
(19–74)
8

56.5
(20–92)
10

91 (52.3)
83 (47.7)

21
14

48
59

22
10

0.035

82 (47.1)

16

54

12

0.430

Comorbid condition, n (%)
Hypertension
Diabetes mellitus
COPD/Asthma
CAD/CHF
Malignancy
Pregnancy

33 (18.9)
26(14.9)
16 (9.2)
14 (8)
6 (3.4)
1 (0.6)

9
10
3
5
0
0

13
6
6
4
2
0

10
10
7
5
4
1

0.169
<0.001
0.022
0.282
0.017
NA

Smoking, n (%)
Alcohol, n (%)

56 (32.2)
24 (13.8)

10
3

33
12

13
9

0.523
0.078

ACEI/ARB use, n (%)
Ibuprofen use, n (%)

18 (10.3)
8 (4.6)

6
1

9
6

3
1

0.543
0.543

Symptoms on admission, n (%)
Fatigue
Cough
Fever
Myalgia
Dyspnea
Sore throat
Nasal discharge
Sputum
Headache
Diarrhea
Loss of taste and/or smell

127 (72.9)
125 (71.8)
104 (60)
99 (56.9)
42 (24.1)
56 (32.2)
27 (15.5)
25 (14.4)
23 (13.2)
10 (5.7)
8 (4.5)

21
22
17
19
6
13
5
4
6
4
0

80
83
66
62
23
34
18
13
13
3
7

25
20
20
18
13
9
4
8
4
3
1

0.257
0.071
0.608
0.994
0.035
0.859
0.653
0.151
0.930
0.166
0.194

3 (0-13)

3 (0-14)

5 (1-14)

0.060

Sex
Male, n (%)
Female, n (%)
Contact with
COVID-19, n (%)

Duration of symptoms prior to hospital
admission, days Median (min–max)
3 (0-14)

P-value

0.003

COPD: chronic obstructive pulmonary diseases; CAD: coronary artery diseases; CHF: congestive heart failure; ACEI: angiotensin
converting enzyme inhibitor; ARB: angiotensin receptor blocker.

suspected patient nasopharyngeal swab PCR was positive
for H. influenzae. The patients with a positive bacterial
PCR test received AZ in combination.
The median duration of hospitalization was 4 days (0–
28) (Table 6). A total of 15 patients (8.5%) were transferred
to the ICU because of worsening respiratory function. Of
the patients, 165 (93.7%) were discharged from the hospital,
4 (2.2%) died outside the ICU, and 5 were still in the ICU
at the time of writing. Among deceased patients, 3 were
confirmed cases, and one was radiologically diagnosed.

414

Patients who were classified as having severe pneumonia
had a higher duration of hospitalization, higher rate of
ICU transfer, and higher rate of mortality.
Among the 4 deceased patients, one patient was 59
years old with Child class C liver cirrhosis, one was 74 years
old with infective endocarditis and septic embolization,
one was 83 years old with chronic renal failure, and the
last patient was 92 years old with aplastic anemia.
A total of 166 patients (95.4%) received HQ alone or
in combination: 23 (13.2%) patients received HQ alone,
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Table 2. Vital signs and MEWS scores of probable/confirmed COVID-19 patients at the time of hospitalization and during the
hospitalization period.

Duration of fever, n (%)
< 2 days
2–5 days
>5 days
MEWS at admission, n (%)
0–1 points
>2 points

Total cases
n: 174 (%)

Mild disease
n: 35

Moderate disease
n: 107

Severe disease
n: 32

108 (62.1)
52 (29.9 )
14 (8)

26
8
1

67
33
7

15
11
6

30
5

100
7

12
20

142 (81.6)
32(18.4)

The highest respiratory rate n (%)
<24 /min
24–30 /min
>30 /min

141 (81)
20 (11.5)
13 (7.5)

31
3
1

99
5
3

11
12
9

Oxygen support n (%)
Not required
Nasal oxygen
Oxygen with mask

141 (81)
20 (11.5)
13 (7.5)

31
3
1

100
3
4

10
14
8

P-value

0.121

<0.001

<0.001

<0.001

MEWS: Modified early warning score.

113 (64.9%) received HQ plus AZ, and 30 received HQ
plus AZ plus FAV (Table 7). FAV was used in a total of 32
(18.4%) cases. Two patients received FAV monotherapy,
whereas the remaining 30 received FAV as a sequential (n
= 21) to the initial regimen or in combination (n = 9).
Lopinavir/ritonavir was used in 3/174 in patients. One
was a woman with an 18-week pregnancy and others
received LPV/r after suboptimal response to initial HQ +
AZ as recommended by the national guidelines. Patients
received prophylactic anticoagulation with low molecular
weight heparin according to national guidelines
recommendation.
Nausea/vomiting were a problem in 11/162 (6.3%)
patients. Of 165 patients who had a control transaminase
level, 16 (9.2%) had elevated transaminases which tended
to normalize in the follow-up. In the patients who were
in the FAV-treated group, both adverse reactions were
more frequent: nausea/vomiting in the HQ group and HQ
plus AZ group were 1/23 (4.3%), 5/106 (4.5%), whereas
5/28 (17.9%) in the FAV-containing regimen (P: 0.038).
Transaminase elevation in the HQ group and HQ plus
AZ group were 1/22 (4.5%), 3/105 (2.9%), whereas it was
present in 10/28 (35.7%) in the FAV-containing regimen
(P < 0.001). There was no significant QT prolongation,
or arrhythmia in this case series. None of the patients
discontinued antiviral therapy due to an adverse reaction.
Four patients (2.2%) died. Five were still in the
ICU at the time of writing. The median time to clinical
6

improvement on therapy was 2 (1–20) days, and to
defervescence was 2 (2–12) days (Table 7).
The median duration of hospitalization was different in
three treatment groups (P: 0.001). The HQ group had the
minimum, and the FAV group had the maximum duration
of hospital stay (2 days vs 7.5 days, P < 0.001). There was
also a significant difference between the HQ and HQ plus
AZ group in terms of duration of hospitalization (P <
0.001).
4. Discussion
In this case series with prospective data collection, we
summarized the characteristics, treatment regimens, and
outcomes of the 174 probable/confirmed COVID-19
patients admitted to a Turkish university hospital
consecutively during the pandemic. Among the study
group, 69% were confirmed, and 31% were probable cases.
ICU transfer rate was 8.5%, and the overall case fatality
rate was 2.2%.
The median age of the patients was 45.5 years, and only
13.8% of the patients were older than 65 years of age. The
relatively younger age profile of our cohort may possibly be
explained by the fact that Turkey has one of the youngest
populations among OECD countries6. In addition, early
nationwide strict lockdown procedures were applied
for those >65 years old possibly leading to a decreased
exposure rate in this age group. On the other hand, the
patients with severe pneumonia at hospital admission were

OECD Data [online]. Website: https://data.oecd.org/pop/young-population.htm#indicator-chart [accessed 06 June 2020].
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Table 3. Diagnostic test results of the probable/confirmed COVID patients.
Total cases
n: 174

Mild disease
n: 35

Moderate disease
n: 107

Severe disease
n: 32

P-value

Positive PCR, n (%)
Negative PCR, n (%)

113 (64.9)
61 (35.1)

23
12

72
35

18
14

0.514

Positive antibody test, n
Negative antibody test, n

7
18

0
2

5
11

2
5

0.010

Chest X-ray, n (%)
Normal
Abnormal
Not performed

62 (35.6)
80 (46)
32 (18.4)

21
7
7

34
52
21

7
21
4

<0.001

Chest CT, n (%)
Normal, no infiltration
Typical infiltration
Indeterminate infiltration
CT not performed

41 (23.5)
80 (46.1)
50 (28.7)
3 (1.7)

35
0
0
0

3
62
40
2

3
18
10
1

Diagnosis, n(%)
Confirmed
Probable
Radiologically diagnosed
Clinically suspected

120 (69)
54 (31)
41 (23.6)
13 (7.4)

28
12
0
12

71
31
31
0

21
11
10
1

<0.001

<0.001

CT: Computerized tomography.

older than those with mild or moderate disease (median
age 56.5, vs 44, and 42 years old, respectively, P: 0.003).
Exposure through international travel was noted in
only one case in this study. This could be related to the
international travel ban to the epidemic regions in the
world issued on February 2020, and suspension of all
domestic and international flights after the identification
of the first case on March 10, 2020. More than half of the
patients (52.9%) had no known contact with a confirmed
COVID-19 case. This highlights the current challenges of
prevention of viral transmission in the population.
Hypertension (18.9%) and diabetes mellitus (14.9%)
were the two leading comorbidities. However, these rates
are within the limits of the estimated prevalence in the
whole population for both diseases7,8 [4]. One-third (5/15)
of those who were transferred to the ICU had hypertension.
Our study design does not enable us to determine
the poor prognostic factors in the course of COVID-19
infection, but the higher frequency of diabetes mellitus or
hypertension among patients who needed to be transferred

to the ICU supports the previous observations [5–7]. A
malignant disease was present in 6% of 5700 COVID-19
patients in New York City [8]. Malignancy was present in
six (3.4%) of our patients, 4 had severe pneumonia, and
unfortunately 2 died.
In a recent paper, Farsalinos et al. pointed out the
lower rates of smokers among COVID-19 patients [9]. In
our study, smoking was observed in 32.2% of the patients,
higher than previous studies [8–11]. According to the
report made by the Turkish National Statistical Institute,
the rate of smokers in the adult population was 23.8%
in 20129 . We found that 7 of 15 patients transferred to
the ICU were active smokers. The relationship between
smoking and the severity of COVID-19 should be clearly
understood in further and larger case series or case-control
studies.
In this study, the median duration of hospital stay was
4 days, comparable to the recently reported New York City
(NYC) cohort of 5700 patients (4.1 days) [8]. Similarly,
13.2% were transferred to ICU (14.2% in NYC cohort) and

7
World Health Organization (2020).COVID-19: Surveilllance, Case Investigation and Epidemiological Protocols [online]. Website: https://www.who.int/
emergencies/diseases/novel-coronavirus-2019/technical-guidance-publications?publicationtypes=df113943-c6f4-42a5-914f-0a0736769008 [accessed
06 June 2020].
8
Arıcı M, Altun B, Erdem Y, Derici Ü, Nergizoğlu G et al. Prevalence, awareness and treatment of hypertension in Turkey (2002) [online]. Website: http://
www.turkhipertansiyon.org/pdf/Turk_Hipertansiyon_Prevalans_Calismasi_Ozeti-1.pdf [accessed 06 June 2020]
9

Global Adult Tobacco Report (2012) (in Turkish) [online]. Website: https://www.tuik.gov.tr/PreTablo.do?alt_id=1042 [accessed 06 June 2020].
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Table 4. Initial laboratory test results of the probable/confirmed COVID-19 patients at the time of admission.
Laboratory parameters

Total

Mild disease

Moderate disease

Severe disease

P-value

Hgb, g/dL (mean ± SD)

13.8 ± 1.8

13.6 ± 2.04

14.0 ± 1.5

13.5 ± 2.39

0.256

WBC (/mm ), median (min–max) 5600 (1000–20,900) 6350 (1000–15,400) 5250 (1800–16300) 6050 (2100–20,900) 0.001
3

LYM (/mm3), (mean ± SD)

1301 ± 641

1312 ± 835

1386 ± 560

1014 ± 531

0.015

NEU (/mm ), median (min–max)

3810 (720–18,750)

4130 (720–13,700)

3260 (740–14.200)

4280 (1300–18,750) 0.002

NLR; median (min–max)

3.1 (0.5–61.5)

3.1 (0.9–20.7)

2.5 (0.15–12.1)

4.6 (1.6–61.5)

<0.001

PLT (/mm ), (mean ± SD)

196000 ±74.190

206000 ± 66.217

194910 ± 74.137

188190 ± 84.105

0.247

CRP; median (min–max)

1.21 (0.1–21.2)

0.81 (0.14–16.9)

0.96 (0.10–24.20)

2.52 (0.50–23.10)

<0.001

ESR; median (min–max)

12 (2–102)

10 (2–102)

11 (2–87)

20 (2–63)

0.223

Procalcitonin; median (min–max) 0.04 (0.01–9.36)

0.04 (0.01–1.01)

0.03 (0.01–0.67)

0.06 (0.01–9.36)

<0.001

D-dimer; median (min–max)

0.44 (0.19–19.5)

0.42 (0.19–5.05)

0.360 (0.19–19.52)

1.01 (0.21–10.39)

<0.001

LDH; median (min–max) (U/L)

193 (96–739)

171 (122–739)

191 (96–639)

239 (140–580)

0.046

Fibrinogen; median (min–max)

375 (118–900)

366 (195–658)

370 (118–827)

448 (137–900)

0.136

Ferritin; median (min–max)

87 (5.8–3248)

61.7 (6.7–2018)

74.3 (5.8–1895)

318 (39–3248)

<0.001

CK ; median (min–max)

81 (7–3249)

83 (16–369)

77 (14–3249)

99 (7–1648)

0.612

CK/MB; median (min–max)

0.9 (0.2–33)

0.9 (0.3–4)

0.9 (0.2–33)

1.3(0.2–5.7)

0.355

Troponin I; median (min–max)

3 (0.7–5397)

3.6 (2.3–35.2)

2.7 (0.7–5397)

5.8 (2.3–53.5)

<0.001

ALT, median (min–max) (U/L)

21 (4–651)

20 (4–651)

23.5 (5–181)

20.5 (7–65)

0.477

AST, median (min–max) (U/L)

26 (8–696)

24 (8–696)

26 (12–141)

28 (15–72)

0.247

Cre; median (min–max), mg/dL

0.74 (0.5–5.7)

0.73 (0.46–5.29)

0.70 (0.41–1,96)

0.84 (0.05–5.73)

0.077

BUN; median (min–max), mg/dL

12 (3–121)

12 (6–39)

11.3 (4–28)

14.4 (5–121)

0.001

TG; median (min–max), mg/dL

89 (30–844)

86 (30–844)

85 (33–454)

98 (45–269)

0.637

3

3

Hgb: hemoglobin, WBC: white blood cell, LYM: lymphocyte, NEU: neutrophill, NLR: neutrophil/lymphocyte ratio, PLT: platelet, CRP:
C-reactive protein, ESR: erythrocyte sedimantation rate, LDH: lactate dehydrogenase, CK: creatine kinase, CK-MB: creatine kinase
myoglobin band, ALT: alanine aminotransferase, AST: aspartate aminotransferase, Cre: creatinine, BUN: blood urea nitrogen, TG:
triglyceride.

case fatality rate was 2.2% (4.8% in NYC cohort). Not surprisingly, patients with severe pneumonia at the time of admission
had a higher rate of ICU transfer, required ventilation support, and higher case fatality rate. Mortality in COVID-19
patients has been reported between 1.4% and 15% in different case series10 [8,11–13]. We must underline that in those case
series, the majority of the patients were still hospitalized at the date of closure of the database. The overall mortality rate
is 2.7% in Turkey11.
Another respiratory bacterial and viral pathogen was detected by multiplex PCR in 19 and 4 patients, respectively. An
early report showed that coinfection with another respiratory pathogen was frequent (14/32) in confirmed COVID-19
patients [14]. In subsequent series, coinfection rates were reported between 2 % and 8%, whereas Zhu et al. reported
rates of coinfection as high as 94.2% in COVID-19 patients, leading to the recommendation of empiric antiinfluenza and
antibacterial treatments [15]. In our study, coinfection with a respiratory pathogen was detected in 23 patients (13.2%).
Low coinfection rates in our patient population discourage use of empiric antimicrobial treatment in COVID-19 patients
and favors current recommendations according to the Turkish National Guidelines.
Cytokine storm is one of the main drivers of COVID-19–related mortality [16]. It can be predicted by some laboratory
values including lymphocyte count, CRP, D-dimer, and ferritin levels. Similar to previous reports [5–8,17–19], we found
lower lymphocyte, high leukocyte and neutrophil counts, higher NLR, higher serum CRP, procalcitonin, d-dimer,
10
Centers for Diseases Control and Prevention (2020). Coronavirus Disease 2019 (COVID-19) [online]. Website https://www.cdc.gov/coronavirus/2019ncov/covid-data/covidview/ [accessed17 May 2020].

Republic of Turkey Ministry of Health (2020). Turkey COVID-19 patient table, 06 June 2020, [online] . Website: https://covid19.saglik.gov.tr [accessed
06 June 2020].
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Table 5. Multiplex bacterial and viral PCR results in the probable/confirmed COVID-19 patients.

Haemophilus influenzae
Streptococcus pneumoniae
Myvoplasma pneumoniae
Adenovirus
Influenza B
Parainfluenza
Coronavirus
Total cases

Confirmed

Radiologically diagnosed

Clinically suspected

9*
4*
0
1
1
1
0
15

5*
1*
1
1*
0
0
1
7

1
0
0
0
0
0
0
1

* Two patients had nasopharyngeal swab PCR positive for H. influenzae, and S. pneumoniae, and one positive for
H. influenza and adenovirus simultaneously.
Table 6. The characteristics of the hospitalization period of probable/confirmed COVID-19 patients.
Total
n: 174

Mild disease
n: 35

Moderate disease
n: 107

Severe disease
n: 32

P-value

Duration of hospitalization, days*

4
(0–28)

3.5
(0–12)

4
(1–15)

7.5
(2–28)

<0.001

Transferred to ICU, n (%)

15 (8.5)

2

5

8

0.001

Duration from hospitalization to
ICU transfer, Days*

5 (0–9)

6 (0–6)

4 (0–7)

5(0–9)

0.139

Discharge, n (%)

165 (93.7)

34

105

26

0.001

Ongoing hospitalization, n (%)

5 (2.8)

1

1

3

Exitus, n (%)

4 (2.2)

0

0

4

*Median (minimum–maximum)
ICU: intensive care unit.

ferritin, LDH, troponin levels were associated with severe
COVID-19 disease. Unfortunately, we could not measure
cytokine levels in this study, a limitation for our results.
In addition, we could not draw a definitive conclusion on
the effectiveness of prognostic markers because the rate of
ICU transfer, critical patients, and mortality were low in
this study.
Despite scarcity of convincing and evidence-based
data, our COVID-19 treatment strategy followed the
updated guidelines of the Turkish Ministry of Health and
in-hospital guidelines developed by a multidisciplinary
team. Patients with pneumonia received HQ and AZ
in combination. Favipiravir was not available in large
quantities, and restricted to use only in critically ill patients
who required ICU in the early days of the pandemic.
After April 14, 2020, National Guidelines amended
recommendations to use FAV in patients with bilateral
pneumonia. In our case series, 13.2% patients received HQ

alone, 64.9% HQ plus AZ, and 18.4% were treated with
regimens including FAV without any significant adverse
effects during the hospitalization period. The durations
of hospital stay, times to defervesce, and symptom
improvement were longer in the FAV-receiving group
but similar between HQ, and HQ plus AZ group. This
outcome is not surprising because FAV was prescribed to
patients failing under first-line regimen (HQ and/or AZ)
or patients who deteriorated during follow-up. Although
HQ monotherapy was reserved for patients without
pneumonia and mild symptoms, we could not detect any
difference between HQ and HQ plus AZ groups in terms
of symptom resolution. We must emphasize that this is an
observational descriptive study, not designed to compare
treatment regimens, so these results should be interpreted
cautiously. There is no efficient or gold-standard treatment
for COVID-19 at the moment12 . A large observational
study from France demonstrated favorable results with

12
Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L et al. Infectious Diseases Society of America Guidelines on the Treatment and Management
of Patients with COVID-19 [online]. April 21, 2020. Website www.idsociety.org/COVID19guidelines [accessed 06 June 2020].
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Table 7. The comparison of outcomes with different therapeutic regimens.
HQ

HQ plus AZ

FAV-containing
regimen

Number of cases, %

23 (13.2)

113 (64.9)

32 (18.4)

Diagnostic criteria
Confirmed cases
Radiologically diagnosed
Clinically suspected

16
3
4

74
31
8

27
5
0

Diseases severity, n
Mild
Moderate
Severe

15
5
3

15
86
12

3
15
14

Nausea/vomiting
Elevation of transaminases

1
1

5
3

5
10

0.038
<0.001

1 (0–4)

1 (0–11)

3 (0–8)

<0.001

Median time to clinical improvement on
therapy*, days

1 (1–6)

1.5 (1–11)

6 (1–20)

<0.001

Median duration of LOS, days

2 (1–21)

4 (1–15)

7.5 (2–24)

0.001

Median time to defervescence, days*

P-value

<0.001

<0.001

* Treatment response analysis was made in 165 patients who had been discharged.
LOS: Length of stay median (minimum–maximum).

HQ treatment; virological cure was obtained in 91.7%
of patients within 10 days whereas the mortality was
0.75% [20]. However, this was a retrospective study with
no randomization. Several other trials failed to show
any benefit from HQ treatment in COVID-19 patients
[21–23]. Data regarding FAV is still scarce and confined
to low-quality studies [23–25]. The results of the ongoing
randomized controlled clinical trials are expected to clarify
the confusion related to treatment of COVID-19.
Our study has several limitations. Firstly, it is a singlecenter observational study with a relatively low number of
patients. Patients were not randomized for treatment, but
were categorized according to severity when allocated to
different therapeutic regimens. Thus, a true comparison
between different regimens was not possible. We could not
perform a risk factor analysis for disease progression, or
outcomes as the number of patients who had a complicated
clinical course was low.

In conclusion, we observed a low mortality rate in a
series of 174 patients with COVID-19 admitted early to
the hospital and given antiviral therapy. Our results may
warrant further investigation of the combined effects of
these practices.
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